DBV Technologies (NASDAQ:DBVT) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of DBV Technologies (NASDAQ:DBVT - Free Report) from a hold rating to a sell rating in a research report released on Friday.

DBVT has been the topic of several other reports. The Goldman Sachs Group upgraded shares of DBV Technologies to a "sell" rating and set a $7.25 price objective on the stock in a report on Thursday, May 29th. JMP Securities restated a "market outperform" rating and issued a $21.00 price objective on shares of DBV Technologies in a report on Thursday, June 26th. Citigroup reiterated an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. HC Wainwright boosted their price target on shares of DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a research note on Monday, May 5th. Finally, Lifesci Capital upgraded shares of DBV Technologies to a "strong-buy" rating in a research note on Thursday, June 26th. Two equities research analysts have rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $14.75.

DBV Technologies Trading Up 3.0%

DBVT traded up $0.29 on Friday, hitting $10.00. The company had a trading volume of 55,371 shares, compared to its average volume of 192,294. The firm has a market cap of $273.90 million, a P/E ratio of -2.03 and a beta of -0.59. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $12.78. The company's fifty day moving average price is $9.65 and its 200 day moving average price is $7.06.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.